EP1824474A1 - Wurmmittel - Google Patents

Wurmmittel

Info

Publication number
EP1824474A1
EP1824474A1 EP05823841A EP05823841A EP1824474A1 EP 1824474 A1 EP1824474 A1 EP 1824474A1 EP 05823841 A EP05823841 A EP 05823841A EP 05823841 A EP05823841 A EP 05823841A EP 1824474 A1 EP1824474 A1 EP 1824474A1
Authority
EP
European Patent Office
Prior art keywords
composition
anthelmintic
praziquantel
anthelmintic composition
oxyclosanide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05823841A
Other languages
English (en)
French (fr)
Inventor
Ernest Schay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Animal Health GmbH
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Publication of EP1824474A1 publication Critical patent/EP1824474A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides

Definitions

  • This invention relates to an anthelmintic composition.
  • Praziquantel and Oxyclosanide are known anthelmintics and, for this purpose, are generally available in suspensions. Although fairly effective, the suspensions do suffer the disadvantage that they are difficult to formulate and are relatively limited as to the amount of immediately bioavailable active compound that they contain.
  • an anthelmintic composition comprising an active ingredient selected from any one or more of Praziquantel, Closantel Sodium, Levimasole and Oxyclosanide dissolved in propylene glycol.
  • compositions to contain between 0.5 and 4%m/v Praziquantel, preferably 2.8%m/v Praziquantel; alternatively for the composition to contain between 1 and 5%m/v Levimasole, preferably 2.5 to 3.75%m/v Levimasole; further alternatively for the composition to contain between 1 and 5%m/v Oxyclosanide, preferably 2.55% Oxyclosanide; still further alternatively for the composition to contain between 1 and 4%m/v Closantel Sodium, preferably 2.5% Closantel Sodium.
  • compositions according to the present invention may contain Chlorbutanol and/or benzyl alcohol.
  • Preferred concentrations of Chlorbutanol are 2 to 5%m/v, in particular 3,3 to 4,l%m/v; preferred concentrations of benzyl alcohol are 1 to 4%m/v, in particular 2,3 to 2,8%m/v.
  • a suitable amount of an active ingredient selected from Praziquantel, Levimasole and Oxyclosanide was dissolved in propylene glycol to provide the solutions of varying concentration. These solutions were tested against suspensions that are available on the market to find concentrations in solution have the same efficacy as suspensions. The results are shown in table below.
  • Solution 2 uses has a higher concentration of Praziquantel than the Endotape Suspension. This concentration was selected simply to match that of Solution 1 but it has nonetheless been found that Solution 2 is effective against a much broader spectrum of tape worms than the Endotape Suspension.
  • Chlorbutanol and benzyl alcohol are defined as preservatives, in this formulation they function as free radical scavengers, possibly due to their OH groups. According to this theory, degradation releases free radicals, and these free radicals function as a catalyst for further degradation. Hence the preservatives, by functioning as free radical scavengers, retard the degradation process.
  • solutions of the invention are easy to formulate, contain less excipients and are more effective than prior art suspensions and highly effective. It will be appreciated, however, that many other embodiments of anthelmintic solutions exists which fall within the scope of the invention, particularly as regards the concentration of the active ingredient.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP05823841A 2004-12-10 2005-12-08 Wurmmittel Withdrawn EP1824474A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ZA200410001 2004-12-10
PCT/EP2005/013139 WO2006061214A1 (en) 2004-12-10 2005-12-08 Anthelmintic composition

Publications (1)

Publication Number Publication Date
EP1824474A1 true EP1824474A1 (de) 2007-08-29

Family

ID=36267185

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05823841A Withdrawn EP1824474A1 (de) 2004-12-10 2005-12-08 Wurmmittel

Country Status (3)

Country Link
EP (1) EP1824474A1 (de)
WO (1) WO2006061214A1 (de)
ZA (1) ZA200704633B (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563554B2 (en) 2009-03-17 2013-10-22 Concert Pharmaceuticals, Inc. Deuterated pyrazinoisoquinoline compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ247278A (en) * 1991-02-12 1995-03-28 Ancare Distributors Veterinary anthelmintic drench comprising a suspension of praziquantel in a liquid carrier
NZ248486A (en) * 1993-08-24 1996-07-26 Ashmont Holdings Limited Subst Stable anthelmintic formulation containing closantel and one or more avermectins or milbemycins in a glycol based solvent
AU711820B3 (en) * 1996-07-30 1999-10-21 Ashmont Holdings Limited Anthelmintic formulations
US6429211B1 (en) * 2000-05-23 2002-08-06 Bayer Corporation Praziquantel compounds for treating diseases due to Sarcocystis Neospora Toxoplasma and Isospora
AUPR510001A0 (en) * 2001-05-18 2001-06-14 Jupitar Pty Ltd Formulation and method
GB2386066A (en) * 2002-02-28 2003-09-10 Norbrook Lab Ltd Long-acting parasiticidal composition with improved bioavailability comprising a salicylanilide, a further anti-parasitic compound & a polymeric species
AU2002952597A0 (en) * 2002-11-11 2002-11-28 Schering-Plough Pty. Limited Topical parasiticide formulations and methods of treatment
HUE032009T2 (en) * 2003-04-04 2017-09-28 Merial Inc Veterinary preparations for topical veterinary use
US7666444B2 (en) * 2004-02-02 2010-02-23 Wyeth Antiparasitic composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2006061214A1 *

Also Published As

Publication number Publication date
ZA200704633B (en) 2008-09-25
WO2006061214A1 (en) 2006-06-15

Similar Documents

Publication Publication Date Title
ES2224651T3 (es) Metodo para estabilizar composiciones farmaceuticas por medio del uso especial de un antioxidante.
KR100854056B1 (ko) 점안액
EP3042646B1 (de) Pharmazeutische zusammensetzungen mit erwünschter bioverfügbarkeit
US20090137651A1 (en) Pharmaceutical composition for external use
US20090176887A1 (en) Biocidal Compositions and Methods
EP3895694A1 (de) Formulierungen aus bendamustin
DK163637B (da) Fremgangsmaade til fremstilling af et stabilt, vandigt praeparat indeholdende ivermectin
CA2476520A1 (en) Long acting parasiticidal composition containing a salicylanilide compound, a polymeric species and at least one other anti-parasitic compound
NZ599669A (en) Compositions containing alpha-2-adrenergic agonist components
RU2745317C2 (ru) Фармацевтическая композиция, включающая дорзоламид и бримонидин
MXPA02000849A (es) Composicion oftalmica que comprende cetotifeno.
JP2002527391A (ja) ビタミンａおよびビタミンｅを含む眼科用組成物の使用
CA2405378C (en) Stable taurolidine electrolyte solutions
US9901576B2 (en) Stable formulation of phenobarbital sodium injection
WO2006061214A1 (en) Anthelmintic composition
DE102018220631A1 (de) Wässrige Zusammensetzung, insbesondere zur Behandlung von Schleimhaut und/oder Wunden
CA2230805A1 (en) Preservative for emulsion and emulsion containing same
JP2001261552A (ja) 点眼液用保存剤
JPS5989617A (ja) 点眼液
US20090211487A1 (en) Wood Preservative Composition
JP4132807B2 (ja) ヨウ素系濃縮防殺菌剤組成物
JP4892291B2 (ja) 眼科用防腐組成物
JP2005270214A (ja) ホルムアルデヒド放散阻止・消臭・抗菌組成物
JP2005036000A (ja) 容器への吸着を防止した外用抗真菌組成物
JP2004331606A (ja) ヨウ素安定化担体、非水溶性固体防殺菌剤組成物及び非水溶性固体防殺菌剤組成物の製造方法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070710

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

17Q First examination report despatched

Effective date: 20071017

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BAYER ANIMAL HEALTH GMBH

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20081111